

MATERIAL SAFETY DATA SHEET

VEDCO, Inc.
Phone No. (816) 238-8840
Page 1 of 2

5503 Corporate Drive, St. Joseph, MO 64507
TranquiVed Injection, 20 mg/mL xylazine
MSDS Date: 1/14/98 (Original)
5/17/2011 (Revised)

Product Name: TranquiVed Injection, 20 mg/mL xylazine

1. INGREDIENTS: (% w/w), unless otherwise noted

COMPONENT	CAS#	%	EXPOSURE LIMITS, ppm	
			OSHA PEL	ACGIH TLV (mg/m ³)
Xylazine hydrochloride	23076-35-9	2	Not established (NE)	

This document is prepared pursuant to the OSHA Hazard Communication Standard (29 CFR 1910.1200). Only those ingredients composing $\geq 1\%$ ($\geq 0.1\%$ for carcinogens or suspect carcinogens) of the formula (w/w) and which have been identified as hazards are listed.

2. PHYSICAL DATA:

APPEARANCE: Liquid
COLOR: Colorless
ODOR: None
Other physical data have not been determined.

pH: 4.5-5.5
SPECIFIC GRAVITY: 1.0035-1.0065

3. FIRE AND EXPLOSION HAZARD DATA:

This has not been evaluated.

EXTINGUISHING MEDIA: Water spray, carbon dioxide, dry chemical powder, or foam.

SPECIAL FIREFIGHTING PROCEDURES: Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

4. REACTIVITY DATA:

This has not been evaluated. The product is stable under normal storage conditions. Exposure to sunlight should be avoided.

5. ENVIRONMENTAL AND DISPOSAL INFORMATION:

ACTION TO TAKE FOR SPILLS/LEAKS: Mop up and wash down area with water.

DISPOSAL METHOD: Dispose of contaminated product and materials used in cleaning up spills or leaks in a manner approved for this material. Consult appropriate federal, state and local regulatory agencies to ascertain proper disposal procedures.

6. HEALTH HAZARD DATA:

EYES: This product may be absorbed through the conjunctiva.

SKIN: This product may be absorbed dermally.

RESPIRATORY: This product may be absorbed after inhalation.

INGESTION: This product may be absorbed after oral consumption.

EFFECTS: The effects of exposure resulting from absorption may include depression of respiration and a decrease in blood pressure.

SYMPTOMS: A person that has absorbed this product or through accidental parenteral injection has been exposed may experience some or all of the following: fatigue with ptosis (falling), muscle relaxation, decreased sensitivity to pain, pronounced dryness of mouth, paleness of skin.

MATERIAL SAFETY DATA SHEET

VEDCO, Inc.

Phone No. (816) 238-8840

Page 2 of 2

5503 Corporate Drive, St. Joseph, MO 64507

TranquiVed Injection, 20 mg/mL xylazine

MSDS Date: 1/14/98 (Original)

5/17/2011 (Revised)

7. FIRST AID:

EYES: Flush with copious amounts of water for at least 15 minutes.

SKIN: Wash with soap and water.

INGESTION: Give liquids if conscious, induce vomiting, repeat until clear.

RESPIRATION: Move to fresh air. Provide artificial respiration if needed.

Seek medical attention immediately if excessive exposure occurs. A physician or a poison control center should be consulted.

8. HANDLING PRECAUTIONS:

During manufacturing or handling of liquid wear appropriate NIOSH/MSHA-approved respirator, chemical-resistant gloves, safety goggles and outer protective clothing.

SPECIAL PRECAUTIONS TO BE TAKEN IN HANDLING AND STORAGE: Exercise reasonable care and caution.

REGULATORY INFORMATION: (Not meant to be all-inclusive--selected regulations represented.)

NOTICE: The information herein is presented in good faith and believed to be accurate as of the effective date shown above. However, no warranty, express or implied, is given. Regulatory requirements are subject to change and may differ from one location to another; it is the buyer's responsibility to ensure that its activities comply with federal, state or provincial, and local laws. The following specific information is made for the purpose of complying with numerous federal, state or provincial, and local laws and regulations. See MSDS for health and safety information.

U.S. REGULATIONS: SARA HAZARD CATEGORY: This product has been reviewed according to the federal EPA "Hazard Categories" promulgated under Sections 311 and 312 of the Superfund Amendment and Reauthorization Act of 1986 (SARA Title III) and is considered, under applicable definitions, to be exempt from reporting requirements. Nevertheless, potential reporters should check with their state emergency response commissions to determine if this product must be reported under applicable state requirements.